The Phoenix acquisition: a strategic foothold in the US market
The global CDMO market is forecast to double by 2032—yet specialist filling capacity remains a critical bottleneck for the industry. As demand for GLP-1s, biosimilars, and ADCs explodes, securing a partner with the right scale and regulatory pedigree on American soil is no longer just an operational need; it is a strategic imperative.
Download our free article to explore why the Phoenix acquisition is a pivotal moment for ROIS, how it tackles the industry’s manufacturing bottleneck, and what this expansion means for your US-based programs.
